Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
Crossref DOI link: https://doi.org/10.1007/s12325-020-01274-5
Published Online: 2020-03-15
Published Print: 2020-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Moran, Kellyn
Null, Kyle
Huang, Zhongwen
Lissoos, Trevor
Kane, Sunanda
Funding for this research was provided by:
Takeda Pharmaceuticals U.S.A.
Text and Data Mining valid from 2020-03-15
Version of Record valid from 2020-03-15
Article History
Received: 18 February 2020
First Online: 15 March 2020